,70 As already discussed, the IgE/FcεRI pathway is considered a major disease driver in FA;71 therefore, ligelizumab is viewed as a promising candidate molecule to be investigated in the management of patients with FA. The gene discussed is IGHE; the disease is Friedreich ataxia.